Stefano Colloca Selected Research

Persistent Infection

8/2016	Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.
5/2016	Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.
5/2014	Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefano Colloca Research Topics

Disease

18	Infections 06/2022 - 05/2005
16	Malaria 01/2018 - 02/2006
10	Vaccinia 01/2020 - 05/2014
9	Neoplasms (Cancer) 01/2020 - 01/2008
4	Falciparum Malaria (Plasmodium falciparum Malaria) 01/2013 - 12/2011
3	COVID-19 01/2022 - 01/2021
3	Viremia 04/2017 - 02/2006
3	Persistent Infection 08/2016 - 05/2014
3	Communicable Diseases (Infectious Diseases) 12/2015 - 03/2012
2	Rabies (Hydrophobia) 04/2021 - 01/2020
2	Chronic Hepatitis C 08/2016 - 05/2016
2	Respiratory Tract Infections (Respiratory Tract Infection) 08/2015 - 01/2015
2	Tuberculosis (Tuberculoses) 03/2015 - 03/2012
2	Bites and Stings (Sting) 03/2015 - 12/2012
1	Colorectal Neoplasms (Colorectal Cancer) 01/2020
1	Microsatellite Instability 01/2020
1	Junctional Epidermolysis Bullosa (Epidermolysis Bullosa Letalis) 11/2018
1	Visceral Leishmaniasis (Kala Azar) 05/2017
1	Leishmaniasis 05/2017
1	Papillomavirus Infections 02/2017
1	Ebola Hemorrhagic Fever 01/2017
1	Reinfection 08/2016
1	Virus Diseases (Viral Diseases) 05/2016
1	Vesicular Stomatitis 04/2016
1	Respiratory Tract Diseases (Respiratory Tract Disease) 08/2015
1	Injection Site Reaction 08/2015
1	Lung Diseases (Lung Disease) 08/2015
1	Necrosis 01/2014
1	Human Influenza (Influenza) 01/2013
1	Acquired Immunodeficiency Syndrome (AIDS) 03/2012
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2012
1	Hepatitis 02/2006

Drug/Important Bio-Agent (IBA)

37	VaccinesIBA 01/2022 - 02/2006
21	AntigensIBA 01/2020 - 02/2009
12	Proteins (Proteins, Gene)FDA Link 06/2022 - 05/2005
5	Neutralizing AntibodiesIBA 01/2020 - 05/2014
4	AntibodiesIBA 01/2021 - 01/2008
4	EpitopesIBA 01/2018 - 02/2006
3	Adenovirus VaccinesIBA 01/2021 - 05/2014
3	ThrombospondinsIBA 01/2018 - 01/2013
3	Antiviral Agents (Antivirals)IBA 08/2016 - 05/2014
2	Peptides (Polypeptides)IBA 01/2020 - 01/2012
2	Glycoproteins (Glycoprotein)IBA 01/2020 - 04/2016
2	1- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)IBA 04/2015 - 01/2013
2	Malaria VaccinesIBA 01/2013 - 12/2012
2	Merozoite Surface Protein 1 (MSA1)IBA 12/2012 - 12/2011
1	Cancer VaccinesIBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2019
1	KalininIBA 11/2018
1	Papillomavirus Vaccines (HPV Vaccines)IBA 02/2017
1	invariant chain (Ii-Key)IBA 01/2014
1	Synthetic Vaccines (Recombinant Vaccines)IBA 03/2013
1	NucleoproteinsIBA 01/2013
1	Subunit VaccinesIBA 01/2013
1	Recombinant ProteinsIBA 01/2012
1	Biological ProductsIBA 01/2008

Therapy/Procedure

2	Therapeutics 12/2015 - 03/2012
1	Drug Therapy (Chemotherapy) 05/2017
1	Immunotherapy 02/2006